{"id":23265,"date":"2022-04-14T13:22:04","date_gmt":"2022-04-14T12:22:04","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=23265"},"modified":"2022-06-13T13:45:29","modified_gmt":"2022-06-13T12:45:29","slug":"acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/","title":{"rendered":"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides"},"content":{"rendered":"\n<p>Communiqu\u00e9 de presse publi\u00e9 sur le <a href=\"https:\/\/www.biomerieux.com\/corp\/fr\/journalistes\/communiques-de-presse\/specific-diagnostics-acquisition.html\" target=\"_blank\" rel=\"noreferrer noopener\">site de bioM\u00e9rieux<\/a> le 12 avril 2022<\/p>\n\n\n\n<p>Marcy-l\u2019\u00c9toile, France, 12 avril 2022 \u2013 bioM\u00e9rieux, acteur majeur dans le domaine du diagnostic\u00a0<em>in vitro<\/em>, annonce la<strong> <\/strong>conclusion d\u2019un accord pour acqu\u00e9rir Specific Diagnostics, une soci\u00e9t\u00e9 am\u00e9ricaine priv\u00e9e qui a mis au point un syst\u00e8me rapide d&#8217;antibiogramme qui fournit un test de sensibilit\u00e9 aux antibiotiques (AST) ph\u00e9notypique directement \u00e0 partir d&#8217;h\u00e9mocultures positives. bioM\u00e9rieux d\u00e9tient une participation minoritaire dans Specific Diagnostics depuis 2019, et les deux soci\u00e9t\u00e9s avaient sign\u00e9 un accord de codistribution couvrant le march\u00e9 europ\u00e9en en 2021.<\/p>\n\n\n\n<p>Les infections dues \u00e0 des agents pathog\u00e8nes r\u00e9sistants aux antibiotiques \u00e9tant l&#8217;une des principales causes de d\u00e9c\u00e8s dans le monde, la r\u00e9sistance aux antimicrobiens est devenue une menace mondiale. Pour que les cliniciens puissent sauver la vie des patients et optimiser rapidement les traitements, il est essentiel que les r\u00e9sultats et l&#8217;interpr\u00e9tation des antibiogrammes soient rapides et pr\u00e9cis. En plus d&#8217;am\u00e9liorer la prise en charge des patients, le recours aux antibiogrammes rapides r\u00e9duit l\u2019impact de la r\u00e9sistance aux antibiotiques en favorisant la mise en \u0153uvre de programmes institutionnels efficaces de bon usage des antibiotiques. <\/p>\n\n\n\n<p>En parfaite coh\u00e9rence avec la priorit\u00e9 de bioM\u00e9rieux de fournir des diagnostics innovants pour soutenir le bon usage des antibiotiques, le syst\u00e8me SPECIFIC REVEAL Rapid AST fournit, en 5 heures en moyenne, des r\u00e9sultats exploitables en cas d\u2019infection par une bact\u00e9rie \u00e0 Gram-n\u00e9gatif directement \u00e0 partir d&#8217;h\u00e9mocultures positives. Il aide les cliniciens \u00e0 r\u00e9pondre au d\u00e9fi de la prise en charge des infections du sang, en permettant soit une d\u00e9sescalade rapide vers un traitement cibl\u00e9, plus appropri\u00e9 et moins co\u00fbteux, soit une escalade rapide vers un traitement plus efficace en cas d&#8217;infection multi r\u00e9sistante.<\/p>\n\n\n\n<p>Avec l\u2019ajout de SPECIFIC REVEAL Rapid AST, la solution unique et compl\u00e8te de bioM\u00e9rieux contre le sepsis permet l\u2019obtention de r\u00e9sultats d&#8217;antibiogramme le jour m\u00eame pour les bact\u00e9ries \u00e0 Gram-n\u00e9gatif, pour d\u00e9cider d\u2019une th\u00e9rapie cibl\u00e9e et am\u00e9liorer ainsi la prise en charge des patients.<\/p>\n\n\n\n<p>D\u00e9velopp\u00e9 par Specific Diagnostics, et bas\u00e9 sur sa technologie unique et brevet\u00e9e de signature m\u00e9tabolomique, le syst\u00e8me SPECIFIC REVEAL Rapid AST constitue un instrument facile \u00e0 utiliser avec un menu cibl\u00e9, un faible encombrement et une conception modulaire pour un d\u00e9bit adaptable. <\/p>\n\n\n\n<p>Il est con\u00e7u pour r\u00e9pondre aux besoins des laboratoires cliniques. SPECIFIC REVEAL s&#8217;int\u00e8gre parfaitement \u00e0 la suite des &nbsp;\u00ab&nbsp;Solutions Sepsis \u00bb de bioM\u00e9rieux qui comprend BACT\/ALERT<sup>\u00ae<\/sup>&nbsp;VIRTUO<sup>\u00ae<\/sup>, VITEK<sup>\u00ae<\/sup>&nbsp;MS PRIME, BIOFIRE<sup>\u00ae<\/sup>&nbsp;BCID2, VIDAS<sup>\u00ae<\/sup>&nbsp;PCT et VITEK<sup>\u00ae<\/sup>2, et est optimis\u00e9 par le service d\u2019expertise en performance du laboratoire et par l\u2019ensemble des solutions informatiques afin d\u2019en extraire toute la valeur.<\/p>\n\n\n\n<p>L&#8217;ajout de SPECIFIC REVEAL au portefeuille de bioM\u00e9rieux intervient alors que la soci\u00e9t\u00e9 a r\u00e9cemment annonc\u00e9 l&#8217;enregistrement par la FDA de VITEK<sup>\u00ae<\/sup>&nbsp;MS PRIME.&nbsp;<\/p>\n\n\n\n<p>Lire le <a href=\"https:\/\/www.biomerieux.com\/corp\/fr\/journalistes\/communiques-de-presse\/specific-diagnostics-acquisition.html\" target=\"_blank\" rel=\"noreferrer noopener\">communiqu\u00e9 de presse<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Communiqu\u00e9 de presse publi\u00e9 sur le site de bioM\u00e9rieux le 12 avril 2022 Marcy-l\u2019\u00c9toile, France, 12 avril 2022 \u2013 bioM\u00e9rieux, acteur majeur dans le domaine du diagnostic\u00a0in vitro, annonce la conclusion d\u2019un accord pour acqu\u00e9rir Specific Diagnostics, une soci\u00e9t\u00e9 am\u00e9ricaine priv\u00e9e qui a mis au point un syst\u00e8me rapide d&#8217;antibiogramme qui fournit un test de [&hellip;]<\/p>\n","protected":false},"author":139,"featured_media":23271,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.8 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides - French\u00a0National ANTIBIOTIC RESISTANCE Portal<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides - French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l&#039;Antibior\u00e9sistance en France et \u00e0 l&#039;international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/\" \/>\n<meta property=\"og:site_name\" content=\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\" \/>\n<meta property=\"article:published_time\" content=\"2022-04-14T12:22:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-06-13T12:45:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"863\" \/>\n\t<meta property=\"og:image:height\" content=\"567\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides\",\"datePublished\":\"2022-04-14T12:22:04+00:00\",\"dateModified\":\"2022-06-13T12:45:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/\"},\"wordCount\":535,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"en-GB\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/\",\"name\":\"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides - French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg\",\"datePublished\":\"2022-04-14T12:22:04+00:00\",\"dateModified\":\"2022-06-13T12:45:29+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg\",\"width\":863,\"height\":567,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Practical info &amp; communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"News\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"name\":\"French\u00a0National ANTIBIOTIC RESISTANCE Portal\",\"description\":\"INSERM - From science to health\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides - French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/","og_locale":"en_GB","og_type":"article","og_title":"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides - French\u00a0National ANTIBIOTIC RESISTANCE Portal","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/","og_site_name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","article_published_time":"2022-04-14T12:22:04+00:00","article_modified_time":"2022-06-13T12:45:29+00:00","og_image":[{"width":863,"height":567,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"\u00c9milie Noguez","Estimated reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides","datePublished":"2022-04-14T12:22:04+00:00","dateModified":"2022-06-13T12:45:29+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/"},"wordCount":535,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"en-GB"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/","name":"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides - French\u00a0National ANTIBIOTIC RESISTANCE Portal","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg","datePublished":"2022-04-14T12:22:04+00:00","dateModified":"2022-06-13T12:45:29+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/"]}]},{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2022\/04\/Analyses.jpg","width":863,"height":567,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/informations-et-communications\/actualites\/acquisition-par-biomerieux-de-specific-diagnostics-une-societe-innovante-specialisee-dans-les-solutions-dantibiogrammes-rapides\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Practical info &amp; communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/"},{"@type":"ListItem","position":3,"name":"News","item":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/info-communication\/news\/"},{"@type":"ListItem","position":4,"name":"Acquisition par bioM\u00e9rieux de Specific Diagnostics, une soci\u00e9t\u00e9 innovante sp\u00e9cialis\u00e9e dans les solutions d\u2019antibiogrammes rapides"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","name":"French\u00a0National ANTIBIOTIC RESISTANCE Portal","description":"INSERM - From science to health","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-GB"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-13 07:04:47","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/23265"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/comments?post=23265"}],"version-history":[{"count":12,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/23265\/revisions"}],"predecessor-version":[{"id":25101,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/posts\/23265\/revisions\/25101"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media\/23271"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/media?parent=23265"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/categories?post=23265"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/en\/wp-json\/wp\/v2\/tags?post=23265"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}